 Antihelminthic anthraquinones and method of use thereof |
| OF THE INVENTION All patents, patent applications, government publications, government regulations,... |
|
| Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| The invention is directed to a new method of inducing viral mutagenesis which is useful in cell ... |
|
| 2'-Fluoronucleosides |
| OF THE INVENTION The invention as disclosed herein is a compound, method and composition for the ... |
|
| Nucleoside compounds |
| Where the following terms are used in this specification, they are used as defined below. The ... |
|
| Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| OF THE INVENTION In one embodiment, the viral infection is chosen from Flaviviridea viral ... |
|
| Monocyclic L-nucleosides, analogs and uses thereof |
| Where the following terms are used in this specification, they are used as defined below. The term ... |
|
| Storage medium storing catalog information and corresponding audio data |
| It is an object of the present invention to provide a storage medium for storing catalog ... |
|
| Nucleoside compounds and uses thereof |
| The present invention is directed to nucleoside analogs and related compounds, including their ... |
|
| Composition and method for inhibiting platelet aggregation |
| OF THE INVENTION This invention is provides a method of preventing or treating diseases or ... |
|
| Non-infectious HIV particles and uses therefor |
| The present invention relates to HIV mutant constructs comprising a mutant HIV genome which has an ... |
|
|
Nucleic acids encoding high molecular weight major outer membrane protein of moraxella
| Details |
Inventors: Sasaki, Ken; Harkness, Robin E.; Loosmore, Sheena M.; Klein, Michel H.;
Assignee:
Primary Examiner: Walsh; Stephen
Assistant Examiner: Sorensen; Kenneth A.
Attorney, Agent or Firm:
An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, has a molecular mass of about 200 kDa. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein. |
|
DETAILED DESCRIPTION The present invention is directed towards the provision of purified and isolated major outer membrane protein of Moraxella catarrhalis and other Moraxella strains, having an apparent molecular mass of about 200 kDa.
In accordance with one aspect of the invention, there is provided an isolated and purified, outer membrane protein of a Moraxella strain having a molecular weight of about 200 kDa, as determined by SDS-PAGE, or a fragment or an analog thereof.
The outer membrane protein may be substantially in its native conformation (so as to have substantially retained the characteristic immunogenicity of the outer membrane protein in the Moraxella strain) and may be isolated from a M.
catarrhalis strain, such as from M.
catarrhalis 4223.
Such isolated and purified about 200 kDa outer membrane protein is substantially free from non-200 kDa outer membrane protein, phospholipids and lipopolysaccharide of Moraxella.
The about 200 kDa outer membrane protein is at least about 70 wt % pure, preferably at least about 90 wt % pure, and may be in the form of an aqueous solution thereof.
The present invention also provides a purified and isolated nucleic acid molecule encoding an outer membrane protein of a strain of Moraxella having a molecular mass of about 200 kDa, as determined by SDS-PAGE, or a fragment or an analog of the outer membrane protein.
The protein encoded by the nucleic acid molecule may encode a protein containing the amino acid sequence NH.
sub.
2 -Asn-Val-Lys-Ser-Val-Ile-Asn-Lys-Glu-Gln-Val-Asn-Asp-Ala-Asn-Lys-x-Gln-Gly -Ile (SEQ ID No: 2) for Moraxella catarrhalis strain 4223 or containing the corresponding amino acid sequence from other Moraxella strains.
In a further aspect of the present invention, there is provided a purified and isolated nucleic acid molecule having a sequence selected from the group consisting of (a) the sequence set out in FIG.
6 (SEQ ID No: 1), or the complementary sequence thereto; (b) a sequence encoding an about 200 kDa protein of a strain of Moraxella and containing the amino acid sequence NH
|
|
Gene Therapy 
